X
CORT icon

Xponance’s Corcept Therapeutics CORT Stock Holding History

Xponance’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
15,918
-486
-3% -$29.3K 0.01% 679
2026
Q1 		$661K Buy
16,404
+1,922
+13% +$71.9K ﹤0.01% 899
2025
Q4 		$504K Buy
14,482
+686
+5% +$53.9K ﹤0.01% 949
2025
Q3 		$1.15M Buy
13,796
+456
+3% +$33K 0.01% 673
2025
Q2 		$979K Buy
13,340
+5,837
+78% +$423K 0.01% 707
2025
Q1 		$857K Buy
7,503
+73
+1% +$4.44K 0.01% 747
2024
Q4 		$374K Buy
7,430
+1,304
+21% +$68.3K ﹤0.01% 1048
2024
Q3 		$284K Buy
+6,126
New +$218K ﹤0.01% 1112

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's CORT Position: Q2 2026 in Review

Xponance reduced its Corcept Therapeutics (CORT) stake by 3% in Q2 2026, selling an estimated $29.3K and leaving 15,918 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #679.

Xponance first reported a position in CORT in Q3 2024 and has held it in 8 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Xponance held 15,918 shares of Corcept Therapeutics worth $1.38M as of Q2 2026.
  • Xponance sold 486 Corcept Therapeutics shares in Q2 2026, an estimated $29.3K.
  • Corcept Therapeutics made up 0.01% of Xponance's portfolio in Q2 2026, its #679 holding.
  • Xponance first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.